17 February 2017
Resting energy expenditure in the risk assessment of anticancer treatments.
This study, published in the Clinical Nutrition Journal, tries to show how abnormal basal energy metabolism can be associated with higher risk in anticancer treatments (like chemotherapy).
Alterations of nutritional and performance status (PS) are associated with higher risk of chemotherapy toxicity. Increased resting energy expenditure (REE) is frequent in cancer patients and may contribute to cachexia. We investigated whether abnormal energetic metabolism could predict early acute limiting toxicities (ELT) of anticancer treatments.
This observational monocentric study (with 227 patients enrolled) showed how toxicity was associated with abnormal metabolism, with REE the most sensitive parameter to predict toxicity. Therefore the conclusion of this paper was that "abnormal basal energy metabolism identifies patients at higher risk of treatment-related acute complications".
The article details are the following:
- Title: "Resting energy expenditure in the risk assessment of anticancer treatments"
- Authors: Jouinot A, Vazeille C, Durand JP, Huillard O, Boudou-Rouquette P, Coriat R, Chapron J, Neveux N, De Bandt JP, Alexandre J, Cynober L, Goldwasser F.
- Published in: Clin Nutr. 2017 Jan 19. pii: S0261-5614(17)30012-2
The full study can be purchased at the following link: click here